Press Releases August 31, 2026 04:15 PM

Enovis to Participate in the 2026 Wells Fargo Healthcare Conference

Enovis to Present at 2026 Wells Fargo Healthcare Conference

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
ENOV

Enovis Corporation announced its participation in the 2026 Wells Fargo HealthCare conference with its CEO and CFO leading a fireside chat. The event will be webcast live and replayed on the company's website. Enovis is a medical technology company focused on developing clinically differentiated solutions to improve patient outcomes and operational efficiency in healthcare.

Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
ENOV
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Enovis will participate in the 2026 Wells Fargo HealthCare conference with leadership presentations available via webcast.
  • The company focuses on innovation in medical technology targeting improved patient outcomes and clinician efficiency.
  • Participation highlights company engagement with investors and analysts in the healthcare sector.

Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor.

Damien McDonald, Chief Executive Officer, and Ben Berry, Chief Financial Officer, will participate in a fireside chat session at 1:30 p.m. Eastern Time. A link to the live audio webcast, as well as a replay of the event, will be available on the Company’s website under the Investors tab at Events and Presentations.

About Enovis 

Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com and follow us on Facebook, Instagram, LinkedIn and X.  

Investor Contact

Kyle Rose, Vice President, Investor Relations
investorrelations@enovis.com

Media Contact

Rachel Colloff, Sr. Director, Corporate Communications
Rachel.Colloff@enovis.com



Risks

  • Market and investor reaction may be neutral if the presentation lacks new impactful developments.
  • Competition in the medical technology sector may pressure Enovis's growth prospects.
  • Dependence on continued innovation and successful commercialization of medical technologies is critical to company performance.

More from Press Releases

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company Sep 2, 2026 uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease Sep 2, 2026 Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Sep 2, 2026 Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences Sep 2, 2026 Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference Sep 2, 2026